BioCryst Pharmaceuticals, Inc.
BCRX
$7.95
$0.101.24%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 153.67% | 15,790.63% | 100.12% | -90.94% | -10.72% |
| Total Depreciation and Amortization | 1.82% | -0.60% | -84.05% | 567.20% | -2.81% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -11.19% | -2.16% | 11.07% | -0.84% | 6.21% |
| Change in Net Operating Assets | -157.64% | 103.83% | -448.34% | -24.07% | 50.08% |
| Cash from Operations | 0.78% | 250.10% | -427.85% | -163.23% | 702.70% |
| Capital Expenditure | -650.84% | -25.17% | 78.81% | -1,044.07% | 61.94% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -50.98% | 7.59% | 47.46% | 116.10% | 472.62% |
| Cash from Investing | -53.40% | 7.50% | 52.24% | 109.65% | 446.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 20.19% | -14,677.13% | -44.94% | 35.97% | -38.31% |
| Issuance of Common Stock | -22.22% | 43.16% | -- | -- | 657.61% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 27.48% | 35.90% | 56.19% | -1,081.61% | 85.82% |
| Cash from Financing | 20.18% | -14,029.30% | 113.16% | -415.62% | 164.80% |
| Foreign Exchange rate Adjustments | -134.44% | 201.33% | 134.59% | -253.23% | 695.10% |
| Miscellaneous Cash Flow Adjustments | 101.45% | -- | -- | -- | -- |
| Net Change in Cash | 77.19% | -3,138.71% | -92.31% | -61.51% | 418.24% |